EVE is an agent that increases the susceptibility to AIs in patients with breast cancer: it decreases the phosphorylation levels of pER (S167) and is used to limit the E2-independent proliferation of breast cancer cells (AI-resistant breast cancers). Here, PER1 is linked to breast cancer.